Collegium (COLL) to Report Q1 Earnings: Here's What to Expect [Yahoo! Finance]
Collegium Pharmaceutical, Inc. (COLL)
Last collegium pharmaceutical, inc. earnings: 2/27 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.collegiumpharma.com
Company Research
Source: Yahoo! Finance
Let's see how things might have shaped up prior to the announcement. Factors to Consider Collegium generates product revenues primarily from the sales of Xtampza ER, the Nucynta Products, Belbuca and Symproic. Belbuca and Symproic were added to Collegium's portfolio following the acquisition of BioDelivery Sciences International, Inc. in 2022. The top line is likely to have been fueled by growth in the sales of pain drugs, Belbuca and Xtampza ER. The bottom line is expected to have been driven by cost structure optimization. The Zacks Consensus Estimate for total sales in the first quarter is pinned at $148 million. Belbuca prescriptions grew 3.2% in the previous quarter and a similar trend is likely to have driven sales of this drug in the first quarter. COLL renegotiated a major Medicare Part D contract for Belbuca, maintaining its access position and materially reducing the rebate, and won a new Medicare Part D plan for Belbuca, representing approximately 1 million cov
Show less
Read more
Impact Snapshot
Event Time:
COLL
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
COLL alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
COLL alerts
High impacting Collegium Pharmaceutical, Inc. news events
Weekly update
A roundup of the hottest topics
COLL
News
- Collegium Announces $35 Million Accelerated Share Repurchase ProgramGlobeNewswire
- Collegium Pharmaceutical, Inc. (NASDAQ: COLL) was downgraded by analysts at Piper Sandler from an "overweight" rating to a "neutral" rating. They now have a $39.00 price target on the stock.MarketBeat
- Collegium Pharmaceutical, Inc. (NASDAQ: COLL) was downgraded by analysts at Needham & Company LLC from a "buy" rating to a "hold" rating.MarketBeat
- Collegium Pharmaceutical, Inc.'s (NASDAQ:COLL) CEO Looks Like They Deserve Their Pay Packet [Yahoo! Finance]Yahoo! Finance
- Collegium Pharmaceutical, Inc.'s (NASDAQ:COLL) CEO Looks Like They Deserve Their Pay Packet [Yahoo! Finance Canada]Yahoo! Finance Canada
COLL
Earnings
- 5/9/24 - Beat
COLL
Sec Filings
- 5/14/24 - Form 144
- 5/13/24 - Form 8-K
- 5/10/24 - Form DEFA14A
- COLL's page on the SEC website